Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03289273 · clinicaltrials.gov ↗

COMPLETED

Status

1010

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Neoplasms

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)

Sponsor

Bayer